Incorporating the patient perspective on the value of medicines into health technology assessments (HTA) is becoming increasingly important as acknowledged by several prominent HTA agencies. NICE (UK) has employed several measures, including a Citizen’s Council. Canada, particularly in the area of oncology, has a formalized process through which patient input on drug reviews and feedback on recommendations is obtained to ensure patients’ experiences (both good and bad) of living with cancer and undergoing treatment are routinely considered. In Australia, there is a consumer representative on the Pharmaceutical Benefits Advisory Committee (PBAC) and patients have the opportunity to provide written input during the assessment process, although the process of how PBAC consider and incorporate this information into their decision is not transparent. There is a need for a more formalized framework for eliciting meaningful patient input and a more transparent process for how that input is incorporated into the decision making process. This research seeks to outline a novel methodological approach to elicit and quantify patient values in a systematic way for the purpose of treatment evaluation (Patient Value Mapping). The focus of this research is Chronic Lymphocytic Leukemia (CLL) and involves patient participation in multiple research stages. Stage 1 involves conducting exploratory qualitative interviews and semi-structured quantitative surveys to gauge how patients view treatments and what outcomes are most important to them. Stage 2 quantifies the insights from stage 1 using discrete choice based methods, including measuring the relative weightings of importance on each of the outcomes and the associated willingness to pay. Current and proposed treatments are entered into the resulting model and scored based on how well they align with patient values and expectations. The results of this analysis could be incorporated into the HTA evaluation process and used to guide decisions around the value of new medicines.